title: Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates.
abstract: METHODS
  National Tuberculosis Clinical Laboratory, China.
  
  
  OBJECTIVE
  To evaluate the accuracy and feasibility of the MYCOTB MIC plate in anti-tuberculosis drug susceptibility testing.
  
  
  METHODS
  MYCOTB testing of Mycobacterium tuberculosis isolates, the Löwenstein-Jensen (LJ) proportion method and the resurazine microtitre assay (REMA), which is extensively used for in-house assay for minimal inhibition concentration (MIC) testing, were performed simultaneously for comparison. A total of 126 clinical isolates were tested using both MYCOTB and the LJ proportion method against 12 anti-tuberculosis drugs; 80 were also tested using REMA.
  
  
  RESULTS
  Categorical agreement between MYCOTB and the LJ proportion method was 99.2% for rifampicin, ofloxacin, amikacin, kanamycin and cycloserine, and 98.4% for isoniazid and para-aminosalicylic acid; ethambutol (EMB) had the lowest agreement (86.5%). The overall categorical agreement between MYCOTB and REMA ranged between 98.8% and 100%. MYCOTB outcomes, interpreted on day 10 and 21, were stable for all drugs except EMB.
  
  
  CONCLUSIONS
  MYCOTB is a rapid, convenient, quantitative and accurate method for testing both first- and second-line anti-tuberculosis drugs.
authors.affiliation: National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Yu
authors.affiliation: National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
authors.forename: Y-F
authors.initials: YF
authors.lastname: Ma
authors.affiliation: National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
authors.forename: G-L
authors.initials: GL
authors.lastname: Jiang
authors.affiliation: National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
authors.forename: S-T
authors.initials: ST
authors.lastname: Chen
authors.affiliation: National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
authors.forename: G-R
authors.initials: GR
authors.lastname: Wang
authors.affiliation: National Tuberculosis Clinical Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Beimachang Rd, Beijing 101149, China. huanghairong@tb123.org.
authors.forename: H-R
authors.initials: HR
authors.lastname: Huang
mesh_terms: D000583:Amikacin / Q000494:pharmacology; D010131:Aminosalicylic Acid / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology; D002681:China; D003523:Cycloserine / Q000494:pharmacology; D004977:Ethambutol / Q000494:pharmacology; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D007612:Kanamycin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification*; D015242:Ofloxacin / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents; D007612:Kanamycin; D010131:Aminosalicylic Acid; D000583:Amikacin; D004977:Ethambutol; D003523:Cycloserine; D015242:Ofloxacin; D007538:Isoniazid; D012293:Rifampin